Fuller & Thaler Asset Management Inc. Has $124.26 Million Position in Axon Enterprise, Inc $AXON

Key Points

• Fuller & Thaler Asset Management Inc. increased its position in Axon Enterprise by 25.6%, owning 236,250 shares valued at approximately $124.26 million, as revealed in its recent SEC filing.
• Several analysts raised their price targets for Axon Enterprise, with Goldman Sachs setting a new target of $830.00 and Raymond James increasing theirs to $855.00, indicating strong confidence in the stock.
• During its latest quarterly earnings report, Axon Enterprise exceeded expectations with earnings of $2.12 per share, significantly above the consensus estimate of $1.54.

Fuller & Thaler Asset Management Inc. lifted its holdings in shares of Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 25.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 236,250 shares of the biotechnology company's stock after purchasing an additional 48,093 shares during the quarter. Fuller & Thaler Asset Management Inc. owned 0.30% of Axon Enterprise worth $124,255,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of AXON. Vanguard Group Inc. raised its position in Axon Enterprise by 2.2% in the 1st quarter. Vanguard Group Inc. now owns 8,632,008 shares of the biotechnology company's stock valued at $4,540,005,000 after buying an additional 185,571 shares during the last quarter. Capital World Investors grew its stake in Axon Enterprise by 86.4% in the fourth quarter. Capital World Investors now owns 1,815,765 shares of the biotechnology company's stock valued at $1,079,145,000 after purchasing an additional 841,772 shares in the last quarter. Westfield Capital Management Co. LP grew its stake in Axon Enterprise by 29.8% in the first quarter. Westfield Capital Management Co. LP now owns 927,801 shares of the biotechnology company's stock valued at $487,977,000 after purchasing an additional 212,931 shares in the last quarter. GAMMA Investing LLC grew its stake in Axon Enterprise by 58,725.5% in the first quarter. GAMMA Investing LLC now owns 764,731 shares of the biotechnology company's stock valued at $402,210,000 after purchasing an additional 763,431 shares in the last quarter. Finally, Northern Trust Corp grew its stake in Axon Enterprise by 1.2% in the first quarter. Northern Trust Corp now owns 725,720 shares of the biotechnology company's stock valued at $381,692,000 after purchasing an additional 8,794 shares in the last quarter. Institutional investors and hedge funds own 79.08% of the company's stock.

Analysts Set New Price Targets

Several analysts recently issued reports on AXON shares. The Goldman Sachs Group boosted their price target on Axon Enterprise from $730.00 to $830.00 and gave the company a "buy" rating in a research note on Wednesday, May 14th. Raymond James Financial reaffirmed an "outperform" rating and issued a $855.00 price objective (up from $645.00) on shares of Axon Enterprise in a report on Tuesday, August 5th. Morgan Stanley set a $885.00 price objective on Axon Enterprise and gave the company an "overweight" rating in a report on Friday, July 11th. UBS Group reissued a "neutral" rating and set a $840.00 price target (up previously from $820.00) on shares of Axon Enterprise in a report on Tuesday, August 5th. Finally, JMP Securities boosted their price target on Axon Enterprise from $725.00 to $825.00 and gave the stock a "market outperform" rating in a report on Tuesday, July 22nd. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat.com, Axon Enterprise currently has a consensus rating of "Moderate Buy" and a consensus price target of $837.69.

Axon Enterprise Stock Performance

Shares of AXON opened at $754.24 on Monday. The company has a current ratio of 2.95, a quick ratio of 2.71 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $59.21 billion, a price-to-earnings ratio of 186.23, a PEG ratio of 27.68 and a beta of 1.36. The stock has a 50 day moving average of $773.85 and a 200 day moving average of $670.41. Axon Enterprise, Inc has a 12 month low of $346.71 and a 12 month high of $885.91.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The biotechnology company reported $2.12 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.58. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%. The business had revenue of $668.54 million during the quarter, compared to analyst estimates of $641.77 million. During the same period in the prior year, the company earned $1.20 earnings per share. Axon Enterprise's revenue was up 32.6% compared to the same quarter last year. As a group, sell-side analysts forecast that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Insider Buying and Selling

In other Axon Enterprise news, insider Jeffrey C. Kunins sold 7,891 shares of the firm's stock in a transaction dated Thursday, August 14th. The stock was sold at an average price of $750.10, for a total transaction of $5,919,039.10. Following the sale, the insider owned 144,538 shares in the company, valued at $108,417,953.80. This trade represents a 5.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Patrick W. Smith sold 10,000 shares of the firm's stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $831.29, for a total value of $8,312,900.00. Following the sale, the chief executive officer owned 3,053,982 shares in the company, valued at $2,538,744,696.78. The trade was a 0.33% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 53,695 shares of company stock valued at $40,964,638 in the last ninety days. 5.70% of the stock is owned by insiders.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axon Enterprise, Inc (NASDAQ:AXON - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.